XTAL Bio and Leman Biotech Achieve Milestone in Immuno-Metabolic Super-Cytokine Development Project

Recently, the superfactor development project for immunometabolic therapy, a collaboration between XtalPi and Leman Biotech Co., Ltd. ("Leman Bio"), has reached a milestone. XtalPi's intelligent and automated drug discovery platform ID4Inno™ and Leman Bio’s proprietary MetaAI-10 computational model have each played to their strengths in the project research, yielding a significant number of preferred mutants with ultra-high affinity, which will unlock greater potential in the fields of cell therapy and immunometabolic treatment.

It is reported that in this project, XtalPi utilized the intelligent and automated drug discovery platform ID4Inno™ to perform structural simulations on wild-type cytokines and their receptor-bound complexes. This allowed them to obtain crucial information about amino acid residues that play a significant role in protein binding interactions. Additionally, they gained an in-depth understanding of the functional sites responsible for effectively activating receptor pathways and the corresponding matching patterns. This knowledge effectively guided the generation of engineered protein sequences and enabled accurate prediction of their binding affinity with receptors.

After in vitro expression and validation screening based on yeast display technology, it was found that among the sequences computationally obtained by ID4Inno™, there are over 5,000 super factors with binding affinities tens of thousands of times higher than the wild type. These can be used for the further development of innovative drugs for tumor immunotherapy in the next stage.

Notably, such ultra-high affinity is hundreds of times greater than that of similar super-factor affinities recently reported by Stanford University in Science, reaching a world-leading level.

Editor: Mu Mian

Disclaimer: This article is a reprint from PharmNet. The images and text are the property of the original author, and the purpose of the reprint is to convey more information, which does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.